




An Immuno-oncology Company Developing HER-2+ Gastric and Breast Cancer Therapies

27th Annual ROTH Conference

March 8-11, 2015

Laguna Beach, CA

Disclaimer

This presentation is confidential and has been provided to the recipient for information purposes only, and no representation or warranty, express or implied, is made as to the completeness or accuracy of the information contained herein. This presentation does not constitute an offer to purchase securities in Imugene Limited (the “Company”) or an offer to sell, or a solicitation of an offer to buy any securities in the Company. This presentation neither constitutes nor includes a prospectus to offer securities. Further, this presentation does not constitute an offer by the Company to enter into any transaction with any person or a solicitation of an offer to enter into any transaction with the Company in any manner. This presentation is being made only to qualified institutional buyers and institutions that are accredited investors, as those terms are defined under the U.S. federal securities laws and regulations, pursuant to Section 105(c) of the Jump Start Our Business Startups Act of 2012, for the sole purpose of determining whether such persons might have an interest in a contemplated securities offering. This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company. This presentation is not being distributed through mass communication media or addressed to the general public, or to any person other than the immediate audience that is receiving this presentation in person on the date hereof. This presentation must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. By attendance at the presentation each recipient agrees to keep the presentation confidential, not to disclose any information included in the presentation in any manner whatsoever and not to disclose the fact of the presentation or any of the terms, conditions, or other facts with respect thereto. No recipient is permitted to utilize this presentation to make an offer, or to solicit any offer, to enter into any transaction whatsoever with or on behalf of the Company.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Corporate Snapshot




- ASX-listed immuno-oncology company (ASX:IMU)
- Developing a B-cell based immunotherapy, known as HER-Vaxx, for HER-2 positive gastric & breast cancer
- Phase 1 trial completed in patients with HER2+/++ breast cancer
- Phase 1b/2 trial to begin 2H 2015
- Technology originates from Medical University of Vienna, one of Europe's leading cancer institutes

Investment Highlights


Compelling Science	• B-cell peptide cancer immunotherapy that induces an antibody response targeting HER-2 over expressing tumors. Phase 1 complete
Management Team	• Experienced, successful board & management
Investment to Date	• Approximately \$10 million invested to date
News Flow	• Numerous milestone announcements & valuation inflection points over next 12 months
Robust IP	• Strong IP with exclusivity until 2030, granted in all major jurisdictions
Strong Upside	• Targeting improvement over HER-2 antibody, Roche's \$6.4 billion Herceptin

HER-Vaxx: Profile

- Advanced B-cell vaccine designed to stimulate a patient's own immune system to repeatedly attack the cancer
- Stimulates a patient's B cells to produce polyclonal antibodies that target cells with overexpressing HER-2 receptors on their surface
- Targets HER-2 positive cancer - about 20% of patients with gastric cancer are "HER-2 positive"
- HER-Vaxx consists of three peptides from the HER-2 receptor plus an adjuvant




HER-2 Target



Imugene's HER-Vaxx:
x3 peptides fused
together

*Polyclonal
response*



**HER-2
Receptor**

Tumor cell


Binding site of

PERJETA™
pertuzumab

Binding site of

Herceptin®
trastuzumab

HER-Vaxx: Mechanism Of Action



HER-Vaxx: Key Differentiators

- HER-Vaxx peptide sequences identified through extensive computer modelling of HER-2 receptor
- Three sequences selected from analysis: all critical to function of HER-2, including the dimerisation loop of the HER-2 receptor
- Peptides patented worldwide
- When combined with influenza antigens & a virosome, polyclonal response elicited from B cells targets three key areas of HER-2 receptor
- Current commercial antibodies – Herceptin and Perjeta – target two or fewer regions of the HER-2 receptor
- Clinical benefits could include improved efficacy, improved safety, longer administration & lower cost

Clinical Status: Phase I Breast Completed

Design

- n=10
- All metastatic breast cancer patients
- HER-2 +/-
- Life expectancy > 4 months
- Conducted at University of Vienna

Observations

- Patients developed anti-HER-2 antibodies
- Induction of memory T & B cells post vaccination
- Reduction in T reg cells post vaccination, indicating strong vaccine response
- Antibodies induced displayed potent anti-tumor activity

Clinical Endpoints

- 1 Safety and Tolerability
- 2 **Immunogenicity:** antibodies/humoral and cellular responses



*Wiedermann et al.,
Breast Cancer Res Treat
(2010)119:673 - 683*

Phase 1b/2 Trial Design – Gastric Cancer

Combined Phase 1b/2 clinical trial planned to confirm safety,
evaluate optimal dosing and to show efficacy

Phase 1b lead in to Phase II Trial

- Open label
- 18 patients, x3 groups of 6 patients
- Endpoints:
 - Dose of HER-Vaxx to use in Phase II part of study
 - Safety: any HER-Vaxx toxicity
 - Immunogenicity (anti-HER2/neu antibody titers)
 - Test booster schedule (q 4 weeks or 8 weeks)

Phase 2 Trial

- ~68 patients from Australia and Europe
- Efficacy, safety and immune response
- Randomized, blind, placebo controlled
- Endpoints:
 - Overall survival
 - Progression-free survival
- Secondary endpoint:
 - Immune response


Robust Intellectual Property

Patent Title	Description	Patent number	Expiry date	Territories
'Vaccine against cancer diseases that are associated with the HER-2/neu Oncogene'	protects specific HER-2 B-cell epitopes	WO02068474	27 Feb 2022	Granted in Australia, Europe, Canada, the USA and Israel
'HER-2/neu Multi-peptide Vaccine'	protects specific HER2 B-cell epitopes	WO2007118660	11 April 2027	Granted in Australia, Europe, Israel and pending in Canada
'Multi-epitope Vaccine for HER-2/neu-associated Cancers'	claims fusion peptides comprising three noncontiguous B cell epitopes from the extracellular domain of HER-2/neu linked to one another and coupled with a delivery system including a virosome	WO2011020604	18 August 2030	Granted in the USA and pending in Europe.
'Lyophilisation of virosomes'	granted through an exclusive global license from Pevion Biotech, is for a patent covering the virosome vaccine delivery platform, used in the manufacture of "HER-Vaxx", in the field of oncology	WO2006/069719	21 December 2025	Granted in EP, US, CN, AU, Eurasia and SA

Business Development Opportunity

- Begin awareness campaign for technology with potential partners
- Initiate robust Phase 1b/2 clinical trial
- Seek data-driven partners for remaining development of HER-Vaxx in gastric cancer
 - pivotal trial
 - marketing
- Seek partners for alternative applications of HER-Vaxx
 - additional HER-2 indications
 - additional settings within indications

News Flow & Milestones



Recent Licensing Agreements

Date	Licensor	Licensee	Technology/ Product	Dev Status	Amount (USD)	
					Upfront	Total
28-Oct-14	F-Star	BMS	FS-102 targeting HER-2	Phase 1 ready	~\$50m	\$475m
20-Oct-14	NewLink Genetics	Genentech	NLG919	Phase 1	\$150m	\$1,150m
16-Oct-14	Aduro Biotech	Janssen	Several candidates	Discovery	\$30m	\$847m
19-Aug-14	Emergent Biosolutions	Morphosys	ES414	Preclinical	\$20m	\$183m
18-Jun-14	Cellectis	Pfizer	CAR-T therapy program	Preclinical	\$80m	\$299m
27-May-14	CytomX	BMS	Probody platform	Discovery	\$50m	\$348m
17-Mar-14	Five Prime Therapeutics	BMS	Immuno-oncology therapies	Discovery	\$20m	\$351m

Financial Information

- Market capitalization (Mar 3 2015): USD10.4m (AUD13.3m)
- Share price (Mar 3 2015): AUD1.0 cents
- Average daily trade: 1.01m shares
- Shares outstanding: 1,329,912,516
- 2014 loss (June 30 year end): USD1.6m (AUD\$2.1m)*
- Cash and equivalents (Dec 31 2014): USD2.3m (AUD\$3.0m)*

** USD to AUD conversions made using exchange rate of 0.78 USD: 1.00 AUD*

Leadership – Experience and Track Record



Charles Walker
CEO

- Former CEO and CFO of ASX-listed Alchemia
- 20+ years in the life science industry, including a decade in specialist corporate finance in London
- Executed ~50 capital markets transactions as principal and advisor



Paul Hopper
Executive Chairman

- Extensive international & ASX biotech capital markets experience particularly in cancer vaccines
- Head of Life Sciences Desk & Australia Desk at Los Angeles-based investment bank, Cappello Capital Corp



Dr Axel Hoos
Non-Executive Director

- Currently Vice President Oncology R&D at GlaxoSmithKline
- Previously Clinical Lead on Ipilumimab at Bristol-Myers Squibb
- Co-Director of the think-tank Cancer Immunotherapy Consortium; Imugene is his only Board seat worldwide



Otto Buttula
Non-Executive Director

- Extensive & successful experience in investment research & financial services management
- Active & substantial investor in the biotechnology sector with a particular focus on oncology
- Several significant positions in ASX-listed companies including Imugene



Dr Nick Ede
*Head of Manufacturing
& Operations*

- Former CTO Consegna, CEO Adistem Ltd, CEO Mimotopes P/L, COO EQiTX Ltd (ZingoTX & VacTX)
- VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology

Investment Summary

Quality Science	Differentiation	Robust IP	Leadership	Best-in-Class Phase 2 Trial	Best-in-Class Phase II Trial
• The subject of numerous peer reviewed published journals • Medical University of Vienna, one of Europe's leading cancer institutes • Technology developed over 10 years	• HER-Vaxx directed at validated target, HER-2 • HER-Vaxx addresses the multiple targets of Herceptin and Perjeta combined • Herceptin sales of USD \$6.4bn in 2013	• IP portfolio with 2030 horizon	• Leading clinical & scientific experts; experienced management • Board holds significant shares, aligning interests with shareholders	• Phase 2 trial designed to be especially robust & big pharma oriented to support potential future partnerships	• Focused 24 month program to deliver results/value inflection • Attractively priced to capitalize on upcoming milestones

IMUGENE

Imugene Limited (ASX:IMU)


Suite 1, 1233 High Street,
Armadale VIC 3143

Charles Walker
Chief Executive Officer

m: +61 (0) 450 446 990

e: cwalker@imugene.com

w: imugene.com



Forward looking statement

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.